Loading provider…
Loading provider…
Infectious Disease Physician in Bronx, NY
NPI: 1538259338Primary Practice Location
MONTEFIORE MEDICAL CENTER
3415 Bainbridge Ave, Bronx, NY
Primary Employer
Montefiore Medical Center
montefioreeinstein.org
HQ Phone
Get MD Robert's Phone Numberphone_androidMobile
Get MD Robert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
The Warren Alpert Medical School of Brown University
medical.brown.edu
Medical School
Until 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 30 | 42 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 30 | 51 |
| 3 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 30 | 30 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 29 | 41 |
| 5 | 99221Initial hospital inpatient care, typically 30 minutes per day | 21 | 21 |
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Authors: Anthony Mills, Gary Blick
Publication Date: 2014-08
How long is the right interval for assessing antiretroviral pharmacy refill adherence?
Authors: Acri, Trisha L, Grossberg, Robert M, Gross, Robert
Journal: J Acquir Immune Defic Syndr
Oral Human Papillomavirus Infection and Oral Lesions in HIV-Positive and HIV-Negative Dental Patients.
Authors: Richard Smith, Howard Strickler
Publication Date: 2014-12-01
Lead Sponsor: ViiV Healthcare
Collaborators: Janssen, LP
Intervention / Treatment: DRUG: Cabotegravir Tablets, DRUG: Rilpivirine Tablets, DRUG: Cabotegravir Injectable Suspension (CAB LA), DRUG: Rilpivirine Injectable Suspension (RPV LA), DRUG: BIKTARVY Tablets (BIK)
Lead Sponsor: Albert Einstein College of Medicine
Collaborators: National Institute on Drug Abuse (NIDA)
Intervention / Treatment: BEHAVIORAL: Abstinence-reinforcing contingency management intervention, BEHAVIORAL: Performance Feedback intervention
Lead Sponsor: AbbVie
Intervention / Treatment: DRUG: Budigalimab, DRUG: ABBV-382, DRUG: Placebo for ABBV-382, DRUG: Placebo for Budigalimab